Initial Workup for Hypercalcemia
The initial workup for hypercalcemia must begin with simultaneous measurement of serum calcium (corrected for albumin or ionized calcium), intact parathyroid hormone (PTH), and basic metabolic panel including creatinine, followed by targeted testing based on PTH level to distinguish between PTH-dependent and PTH-independent causes.
Core Laboratory Tests
The diagnostic algorithm hinges on the PTH level 1, 2:
First-Line Tests (Order Immediately):
- Serum calcium - both total calcium (corrected for albumin) and ionized calcium if available
- Intact PTH - this is the single most important discriminating test
- Basic metabolic panel - assess renal function and electrolytes
- Serum phosphate
- Albumin - to correct total calcium if ionized calcium unavailable
PTH-Dependent Hypercalcemia (PTH elevated or inappropriately normal):
When PTH is not suppressed (<20 pg/mL), this indicates primary hyperparathyroidism (PHPT) or related disorders 1. Additional workup includes:
- 24-hour urine calcium and creatinine - critical to distinguish PHPT from familial hypocalciuric hypercalcemia (FHH) 3
- Low urinary calcium (<100 mg/24h) or calcium-to-creatinine clearance ratio <0.01 suggests FHH
- Normal to high urinary calcium supports PHPT
- Vitamin D (25-OH) - assess vitamin D status before considering surgery
- Serum creatinine and eGFR - evaluate renal involvement
- Bone density scan (DEXA) - assess skeletal involvement if PHPT confirmed
PTH-Independent Hypercalcemia (PTH suppressed <20 pg/mL):
When PTH is suppressed, malignancy is the most likely cause, but other etiologies must be considered 1, 4:
- PTHrP (parathyroid hormone-related protein) - elevated in most solid tumor malignancies causing hypercalcemia
- Serum and urine protein electrophoresis - screen for multiple myeloma
- 1,25-dihydroxyvitamin D (calcitriol) - elevated in granulomatous diseases (sarcoidosis), some lymphomas
- 25-hydroxyvitamin D - assess for vitamin D intoxication
- TSH - screen for hyperthyroidism
- Chest X-ray or CT chest - evaluate for malignancy or granulomatous disease
- Medication review - thiazides, lithium, calcium supplements, vitamin A, vitamin D
Clinical Context Matters
Your patient's symptoms (fatigue, muscle weakness, joint pain, nausea, constipation, difficulty concentrating) are consistent with mild to moderate hypercalcemia 1. These nonspecific constitutional symptoms occur in approximately 20% of patients with mild hypercalcemia and do not immediately distinguish between causes.
Severity Classification:
- Mild: Total calcium <12 mg/dL (<3 mmol/L)
- Moderate: Total calcium 12-14 mg/dL (3-3.5 mmol/L)
- Severe: Total calcium >14 mg/dL (>3.5 mmol/L) 5
Critical Pitfalls to Avoid
Do not delay PTH measurement - this is the most common error. PTH must be measured simultaneously with calcium, not after calcium is confirmed elevated, as the PTH level guides all subsequent workup 2.
Do not miss FHH - failure to check 24-hour urine calcium in PTH-dependent hypercalcemia leads to unnecessary parathyroid surgery in patients with benign FHH 3. The biochemical overlap between PHPT and FHH is substantial, making urinary calcium essential.
Do not assume malignancy without evidence - while hypercalcemia of malignancy is common in hospitalized patients, approximately 90% of outpatient hypercalcemia is due to PHPT 1. A thorough cancer screening is warranted only if PTH is suppressed.
Algorithmic Approach
- Confirm hypercalcemia → Measure corrected calcium or ionized calcium
- Measure PTH simultaneously → This determines the diagnostic pathway
- If PTH elevated/normal → Check 24-hour urine calcium to exclude FHH, then proceed with PHPT workup
- If PTH suppressed → Pursue malignancy workup (PTHrP, imaging, protein electrophoresis) and other PTH-independent causes (vitamin D levels, medications, granulomatous disease)
- Assess severity → Determines urgency of treatment while workup proceeds
The provided guidelines 5 focus on treatment of hypercalcemia of malignancy rather than initial diagnostic workup, but they underscore that identifying the underlying cause is essential before initiating definitive therapy beyond acute management.